Vioxx and Seroquel lawyers to act in consolidated Actos bladder cancer litigation
This article was originally published in Scrip
Executive Summary
It has come as no surprise that the US federal judge overseeing US product liability cases related to an alleged increased risk of bladder cancer with Takeda’s diabetes product Actos (pioglitazone) has named two plaintiffs’ lawyers with experience in some high-visibility pharmaceutical cases to lead the group. This includes mass tort experts involved with litigation surrounding Merck & Co's now withdrawn Vioxx (rofecoxib) and AstraZeneca's marketed schizophrenia and biopolar disorder drug Seroquel (quietapine fumurate).